Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala Biomedical Center, Husargatan 3, SE-751 23 Uppsala, Sweden.
Vaccine. 2012 Jan 5;30(2):225-30. doi: 10.1016/j.vaccine.2011.11.010. Epub 2011 Nov 10.
We have recently shown that immunization against the extra domain-B (ED-B) of fibronectin, using Freund's adjuvant, reduces tumor growth in mice by 70%. In the present study we compare the immune response generated against ED-B using the non-toxic and biodegradable adjuvant Montanide ISA 720/CpG with the response elicited by Freund's adjuvant. Montanide ISA 720/CpG induced anti-ED-B antibodies with higher avidity and less variable levels between individuals than Freund's. Moreover, the duration of the immune response was longer and the generation of anti-ED-B antibodies in naïve mice was faster, when Montanide ISA 720/CpG was used. We conclude that it is possible to replace the mineral oil based adjuvant Freund's with an adjuvant acceptable for human use, which is a prerequisite for transfer of the ED-B vaccine to the clinic.
我们最近发现，使用弗氏佐剂对纤维连接蛋白的外域-B（ED-B）进行免疫接种，可使小鼠的肿瘤生长减少 70%。在本研究中，我们比较了使用非毒性和可生物降解佐剂 Montanide ISA 720/CpG 产生的针对 ED-B 的免疫应答与弗氏佐剂引起的应答。Montanide ISA 720/CpG 诱导的抗 ED-B 抗体具有更高的亲和力和个体之间更一致的水平。此外，当使用 Montanide ISA 720/CpG 时，免疫反应的持续时间更长，并且在 naive 小鼠中更快地产生抗 ED-B 抗体。我们得出结论，有可能用一种可用于人体的佐剂替代矿物油基佐剂弗氏佐剂，这是将 ED-B 疫苗转移到临床的前提条件。
